How are chromosomal abnormalities treated?
Apr 24, 2022
Source: Cainiu Health
Dr. Yang Qiong
Introduction
Chromosomal abnormalities are congenital genetic disorders. If they affect fertility, individuals should visit a hospital for relevant examinations and targeted treatment. In cases of chromosomal abnormalities, most patients may consider undergoing third-generation in vitro fertilization (IVF). Third-generation IVF enables the identification and exclusion of embryos with chromosomal abnormalities, allowing selection of chromosomally normal, developmentally healthy embryos for intrauterine transfer and subsequent delivery.
Chromosomal abnormalities typically occur during embryonic development and may lead to miscarriage or infertility. Currently, there is no established medical treatment for chromosomal abnormalities. How are chromosomal abnormalities treated?
How Are Chromosomal Abnormalities Treated?
Chromosomal abnormalities are congenital genetic disorders. If they affect fertility, individuals should consult a healthcare provider for relevant diagnostic testing and symptom-based management. For patients with chromosomal abnormalities who wish to conceive, third-generation in vitro fertilization (IVF) is often recommended. This technique enables preimplantation genetic testing (PGT) to identify embryos with chromosomal abnormalities; only chromosomally normal embryos are selected for uterine transfer and subsequent pregnancy. In cases where natural conception occurs but chromosomal abnormalities are detected, the resulting embryos frequently carry genetic defects. Therefore, individuals diagnosed with chromosomal abnormalities must undergo genetic testing and receive appropriate clinical management at a medical facility. No pharmacological treatments are currently available.
Generally, nuchal translucency (NT) screening can be performed during early pregnancy (typically between 11–14 weeks’ gestation) to assess the risk of fetal chromosomal abnormalities. Subsequently, maternal serum screening for Down syndrome (commonly referred to as “triple” or “quadruple” screening) may be conducted between 15–20 weeks’ gestation. If either NT screening or Down syndrome screening yields high-risk results, further diagnostic evaluation is recommended—such as non-invasive prenatal testing (NIPT) or amniocentesis—to confirm the diagnosis.
Current therapeutic approaches primarily focus on symptomatic management and surgical correction of associated organ malformations. Gene therapy, cell therapy, and replacement therapies are under active investigation but remain experimental. Overall, chromosomal abnormalities pose significant therapeutic challenges, and treatment outcomes are generally suboptimal. We hope this information has been helpful!
